Clinical role of serum Copeptin in acute coronary syndrome
Manal Abd El Baky Mahmoud1, Menat Allah Ali Shaaban1, Ali Ali Ramzy2
1Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt.
Insights
Copeptin offers superior diagnostic value for acute myocardial infarction (AMI) compared to troponin within the initial three hours of chest pain. This biomarker aids in early AMI diagnosis when troponin levels are not yet indicative.
Area of Science:
- Cardiology
- Biomarker Discovery
- Emergency Medicine
Background:
- Acute myocardial infarction (AMI) diagnosis relies on cardiac biomarkers, but troponin levels may be non-diagnostic in the early hours.
- The 'troponin-blind' period poses a challenge for timely AMI diagnosis and intervention.
- Copeptin, a marker of arginine vasopressin release, is explored for its potential in early cardiac ischemia detection.
Purpose of the Study:
- To evaluate the diagnostic utility of Copeptin in identifying acute myocardial infarction (AMI) during the early phase.
- To compare the diagnostic performance of Copeptin against conventional biomarkers like CK-MB and cardiac troponin I (cTnI) in the initial hours after symptom onset.
- To assess Copeptin's role in differentiating AMI from unstable angina (UA) in patients presenting with chest pain.
Main Methods:
- A study involving 40 patients with suspected acute cardiac ischemia and 10 healthy controls.
- Blood samples were collected at admission and again at 3-6 hours for measurement of CK-MB, cTnI, and Copeptin.
- Receiver Operating Characteristic (ROC) curve analysis was performed to determine diagnostic accuracy.
Main Results:
- In the initial blood samples, Copeptin showed a highly significant difference between the unstable angina (UA) and AMI groups (P < 0.001), unlike CKMB and troponin.
- ROC curve analysis demonstrated 100% sensitivity and specificity for serum Copeptin in distinguishing AMI from UA in the first sample.
- Copeptin levels were significantly elevated in AMI patients compared to UA patients early in the presentation.
Conclusions:
- Copeptin determination is valuable for the early diagnosis of AMI.
- Copeptin exhibits superior diagnostic performance compared to conventional cardiac troponin I within the first three hours of acute chest pain.
- Copeptin can effectively aid in the rapid identification of AMI in emergency settings.
Objective:
To assess the role of Copeptin in diagnosis of acute myocardial infarction in troponin-blind period.
Subjects And Methods:
This study was conducted on 40 patients who presented to emergency department complaining of chest pain and were highly suspicious to have acute cardiac ischemia, in addition to 10 subjects serving as a healthy control group. Blood samples were collected for determination of CK-MB, cTnI and Copeptin. These were measured twice (in patients' group); at 3 h and then at 6-9 h from admission time.
Results:
The first sample revealed a non-significant difference between UA group and AMI group as regards CKMB and troponin, however, high significant difference was found as regards Copeptin (Z = 5.29, P < 0.001). Moreover, ROC curve analysis of serum Copeptin for discriminating AMI group from UA group in the first sample showed diagnostic sensitivity and specificity of 100%.
In Conclusion:
Determination of copeptin in early diagnosis of AMI has diagnostic value being superior to a conventional cTn-I within the first three hours after acute chest pain.
Related Concept Videos
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Coronary Artery Disease III: Clinical Manifestations